Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 5/2021

MIMOSA TENUIFLORA FOR THE TREATMENT OF DAMAGED SKIN – STUDY ON ITS EFFICACY AND TOLERABILITY IN THE TREATMENT OF IRRITATIVE CONTACT DERMATITIS

ALIN CODRUȚ NICOLESCU 1#, ANCA CECILIA NICOARĂ 2*, SÎNZIANA IONESCU 2,3#,
LAURENȚIU SIMION 2,3, MARIA MAGDALENA CONSTANTIN 2,4#, ȘTEFANA BUCUR 2,4,
IOAN ANCUȚA 2,5

1Roma Medical Center for Diagnosis and Treatment, 32-34 Roma Street, Bucharest, 011773, Romania
2“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, Bucharest, 050474, Romania
3Surgery Department I, “Prof. Dr. Al. Trestioreanu”, Oncology Institute Bucharest, 252 Soseaua Fundeni, Bucharest, 022328, Romania
4Dermatology Department II, Colentina Clinical Hospital, Soseaua Stefan cel Mare 19-21, Bucharest, Romania 5Department of Rheumatology, “Dr. I. Cantacuzino” Clinical Hospital, Ioan Movila Street, nr. 5-7, Bucharest, 020475, Romania

Download Full Article PDF

In the context of a striking increase in the number of Irritative Contact Dermatitis (ICD) cases during the challenging COVID-19 pandemic, between March -July 2020, especially among healthcare professionals, we assessed the efficiency of a commercially available barrier cream applied 2 times/day for 1 week. The barrier cream tested is based on Mimosa tenuiflora, an extract from the bark of the tree also known as the “skin tree”. This extract contains many components that participate in all phases of wound healing by accelerating the cicatrisation process and reducing the risk of scarring. The study consisted in visual scoring of the skin condition (analysing xerosis, erythema, scaling and cracks) during the 1st visit and then after 7 days (2nd visit). Patients were also asked to rate the prickling and burning sensation, pain and pruritus, at the same intervals. After 7 days of treatment a Satisfaction Questionnaire was also filled in. The results showed a statistically significant reduction (p < 0.0002) in all targeted parameters, as well as a perception of excellent efficacy and tolerability. The barrier cream tested is a valuable dermato-cosmetic treatment option for ICD